Nordic Life Science 1
IQVIA ADVERTOR I AL “In the borderland between da
ta science and human science, we forecast drug use for a global market. We produce the statistics on the trends and assist our clients with further laboratory and analytical services to enable their planning for next year’s pharmaceutical needs. We want to support our clients in making more informed and smarter decisions allowing them to get breakthroughs to market faster and improve patient outcomes.” IQVIA’s broad network and comprehensive health data have the capacity to extract previously hidden insights, which have an important role to play in the development of effective therapies and medicines to treat and prevent diseases today and in the future. A DVER T OR I A L An example of the reach of IQVIA’s solutions is the collaboration with Genomics England to develop a platform, which will connect non-identified clinical data with non-identified genes to accelerate treatment progress, advance development of new drugs, create more sturdy evidence and increased advances in the development and availability of personalized medicine. The goal of the project is to scan a total of 100,000 genomes. QVIA IS A LEADING GLOBAL PROVIDER of advanced analytics, technology solutions, and clinical research. The company’s goal is to enable customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances. “We usually say that IQVIA works with everything from molecule to market, i.e. from research to the introduction of drugs and treatment,” says Stefan Ohlsson, General Manager at IQVIA Solutions in the Nordic region. IQVIA has a network of approximately 70,000 employees in over 100 countries. IQVIA is on FORTUNE’s list of the World’s Most Admired Companies for the fourth consecutive year. Read more at iqvia.com “We at IQVIA and our industry colleagues are perhaps more relevant now than ever with the work we are doing due to the current corona pandemic,” Stefan evaluates. “We see that the opportunity to use data and advanced technology in collaboration with other actors leads to fantastic opportunities. Based on previous research in this area, and the cooperation made possible by industries and technology, progress has been made faster than expected.” “New demands are of course placed on all parts of the communities. We have postponed a healthcare debt and the use of health data today takes too long and is unnecessarily complicated. There is a lack of strong national governance that reduces the gap between strategy and application. This is an area where we have great opportunities to create better conditions for Sweden to advance its position as an attractive nation for conducting medical research and clinical studies,” concludes Stefan. NLS S T E F A N O H L S S O N